Savosolar Plc – Managers’ Transaction, Jussi Mälkiä, December 2022
Savosolar Plc
Company Announcement 8 March 2023 at 8.30 a.m. (CET)
Savosolar Plc – Managers’ Transaction, Jussi Mälkiä, December 2022 Person subject to the notification requirement | ||
| Name: | Jussi Mälkiä | |
| Position | Member of the Board/Deputy member | |
| Initial Notification | ||
| Reference number: | 26713/5/4 | |
| Issuer | ||
| Name: | Savosolar Oyj | |
| LEI: | 743700J1YZ8IEJAPDL21 | |
| Transaction details | ||
| Transaction date: | 2022-12-29 | |
| Venue: | FIRST NORTH GROWTH MARKET FINLAND (FSME) | |
| Nature of the transaction: | DISPOSAL | |
| Further details: | ||
| Instrument: | Share | |
| ISIN: | FI4000425848 | |
| Volume: | 2580645 | |
| Unit price: | 0.07750 Euro | |
| Aggregated transactions | ||
| Volume: | 2580645 | |
| Volume weighted average price: | 0.07750 Euro | |
SAVOSOLAR PLC
For more information:
Savosolar Plc
Managing Director Jari Varjotie
Phone: +358 400 419 734
E-mail: jari.varjotie@savosolar.com
Savosolar in brief
Savosolar has two business areas: Marine Logistics and Renewable Energy.
Marine Logistics (Meriaura Oy) is a major provider of transport for bulk cargo and demanding project deliveries in Northern Europe, especially in the Baltic Sea and North Sea regions. The company provides its customers with competitive and environmentally sustainable marine transport services, which also reduce carbon emissions from marine transport. Its long-term affreightment agreements, modern fleet and strong market position in renewable energy construction projects enable freight that supports environmentally friendly solutions. As part of Marine Logistics, VG-EcoFuel Oy produces recycled biofuels from bio-oils and recycled oils generated as industrial by-products.
The Renewable Energy (Savosolar Oyj) designs and delivers clean energy production systems as comprehensive deliveries. The systems are built around large-scale solar thermal systems implemented using high-performance solar heat collectors manufactured by the company. Other energy production and storage technologies can also be combined with the systems. The company has taken solar thermal technology to a new level, and its collectors have patented nano-coated direct flow absorbers. With this leading technology, Savosolar enables its customers to produce clean and competitive energy.
Savosolar’s shares are listed on Nasdaq First North Growth Market Sweden under the ticker symbol SAVOS and on Nasdaq First North Growth Market Finland under the ticker symbol SAVOH. www.savosolar.com.
The company’s Certified Adviser is Augment Partners AB, info@augment.se, tel. +46 8-604 22 55.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter24.4.2024 07:00:00 CEST | Press release
Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to low bioethanol deliveries and increased costs. The net currency effects were slightly negative for the Group. Profit before tax was NOK 261 million (NOK 292 million). Earnings per share were NOK 2.01 (NOK 2.32). - We are pleased with the strong result improvement in BioSolutions and the positive sales volume development for the Group, says President and CEO Per A. Sørlie. Contacts: Director Investor Relations, Knut-Harald Bakke, +47 905 79 164 Director Communicat
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-1924.4.2024 07:00:00 CEST | Press release
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve Diagnostics Division base business2 grew by 8%, supported by growth across all regions because of demand for immunodiagnostic products, clinical chemistry tests and advanced staining solutions. As this growth was partially offset by the lower dem
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates24.4.2024 07:00:00 CEST | Press release
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant improvement in kidney function observed with varoglutamstat 600mg BID in VIVIAD over two years based on pre-specified analysis of the estimated glomerular filtration rateCompany plans to explore potential of varoglutamstat in kidney disease in a shift of strategic focus towards inflammatory and fibrotic disorders VIVA-MIND Phase 2 study to be discontinued early, in H2 2024, which will enable accelerated data analysis and inform varoglutamstat development strategyCompany is taking steps to reduce cash utilizatio
Wereldhave Trading update Q1 202424.4.2024 07:00:00 CEST | Press release
Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the Netherlands to further reduce LTVFull Service Center Sterrenburg awarded with the 2024 Kern annual development awardForecast FY 2024 DRPS € 1.75 reiterated Attachment Trading update Q1 2024 Wereldhave N.V.
IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma24.4.2024 07:00:00 CEST | Press release
ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U, a European distributor in the pharmaceutical and nutraceutical industry. Established in 2011 and headquartered in Barcelona, Spain, Cobapharma provides an extensive portfolio of Active Pharmaceutical Ingredients (APIs) as well as nutraceutical ingredients. With 20 employees, Cobapharma represents leading suppliers and generated a revenue of approximately EUR 19 million in the financial year that ended December 31, 2023. ‘Cobapharma is a rapidly growing distributor in the pharmaceutical and nutraceutical industry. Their esteemed reputation for providing high-quality APIs and nutraceutical ingredients perfectly complements our existing portfolio. The alignment of our business models will enhance our ability to serve our customers and partners’ c